헤맙 테라퓨틱스 홀딩스(COAG) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 28.79% | Shs Outstand | 46.7M | Perf Week | 2.02% |
| Market Cap | 2.35B | Forward P/E | - | EPS next Y | 10.4% | Insider Trans | 28.36% | Shs Float | 33.3M | Perf Month | 81.78% |
| Enterprise Value | 2.55B | PEG | - | EPS next Q | -0.73 | Inst Own | 32.91% | Short Float | 4.99% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | 95.85% | Inst Trans | 4.04% | Short Ratio | 4.57 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | 63.92% | ROA | - | Short Interest | 1.66M | Perf YTD | 86.63% |
| Book/sh | -4.25 | P/C | 14.39 | EPS past 3/5Y | - | ROE | - | 52W High | -3.37% ($52.15) | Perf Year | - |
| Cash/sh | 3.5 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 119.09% ($23.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 9.16% 11.71% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.85 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 70.97 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.85 | Sales Q/Q | - | SMA20 | 23.21% ($40.9) | Beta | - | Target Price | $50 |
| Payout | - | Debt/Eq | - | Earnings | 2026/06/03 | SMA50 | 54% ($32.72) | Rel Volume | 1.06 | Prev Close | $47.31 |
| Employees | 72 | LT Debt/Eq | - | EPS/Sales Surpr. | -1.05% - | SMA200 | 58.5% ($31.79) | Avg Volume(3M) | 0.36M | Price | $50.39 |
| IPO | 2026/5/1 | Option/Short | No/Yes | Trades | 4205 | Volume | 386,308 | Change | 6.51% |
Hemab Therapeutics Holdings Inc (COAG) Investment Analysis
What kind of company is Hemab Therapeutics Holdings Inc?
🩸 Hemab Therapeutics (COAG) is a clinical-stage biotech developing treatments for rare hereditary bleeding and clotting disorders. The company targets underserved coagulation disorders with limited existing treatment options, such as Glanzmann thrombasthenia and von Willebrand disease, and is advancing its next-generation antibody-based pipeline from bases in the United States and Europe.
Learn more about Hemab Therapeutics Holdings Inc →Key Events
Is it profitable?
What's the outlook?
Did earnings meet expectations?
Is it growing?
Has the stock risen over the long term?
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 59-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current price $50.39 above the midline ($40.88). Normal upward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
MACD 5.104 > Signal 4.531 in positive zone + Hist positive (+0.573). Trend in progress.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
RSI 71.4 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 91.8.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Key metrics such as PER and PBR are unavailable, so valuation is omitted.
Who owns it?
ETFs holding COAG
How much does it pay in dividends?
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| COAG This Stock | $2.4B | - | - | - | - | +6.5% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 헤맙 테라퓨틱스 홀딩스(COAG)?
헤맙 테라퓨틱스 홀딩스(COAG) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of COAG?
The market cap of COAG is approximately $2.4B, ranking 1,994 within its sector.
What is the 52-week high and low for COAG?
COAG has recorded a 52-week high of $52.15 and a low of $23.00.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.